Reata Pharmaceuticals Inc. Overview
Pro stress-test →Reata Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative therapies including bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company focuses on severe, life-threatening diseases with limited treatment options.
Strategic Profile
Pro stress-test →With a market cap of $6.57 billion, Reata is positioned as a biotech player targeting rare and severe disease indications through a differentiated mechanism of action. The company's pipeline advancement and regulatory progress will determine its clinical and commercial viability in a competitive therapeutic space.
Competitive Landscape
Pro stress-test →Reata competes in the rare disease and mitochondrial dysfunction therapeutic space against other specialty biotech companies and larger pharmaceutical firms with broader portfolios. Direct competitors include other developers of rare disease and metabolic disorder therapeutics, though the Nrf2 activation pathway offers differentiation.
Industry Context
Reata Pharmaceuticals Inc. operates in Rare disease biopharmaceuticals.
Key facts
Founded: 2002 · Headquarters: Plano, Texas (note: anchor provided Irving) · Employees: Not specified in available sources · Revenue: Pre-commercial stage; limited commercial revenue · Market cap: $6.57B